Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) have become the most frequently prescribed agents for the treatment of hyper-cholesterolemia because of the compelling evidence of their effect on reducing cardiovascular event rates.(1.2) They are generally well tolerated and have a favorable safety profile. Although rare, a major adverse event of statins is myopathy, defined as creatine kinase (CK) increase to greater than or equal to10 times the upper limit of normal (ULN) with accompanying symptoms of muscle pain or weakness.(3) If the myopathy is not recognized and drug therapy continues, rhabdomyolysis and acute renal failure may result. Statin treatment is always long term, and thus, attention to the possibility of myopathy continues to be important. There may be significant differences in the frequency of myopathy and/or CK elevations associated with different statins. This study used a pooled analysis to evaluate the frequency of CK elevation associated with fluvastatin treatment.